ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves New Task Orders For RMP Clinical Trials, Holds Up On Additional Grants

February 20, 1981

Fragmin Cuts Risk Of VE By 50 Percent In Study

January 31, 2003

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

April 6, 2012

Rescission Cuts $5-6 Mil. From NCI FY94 Appropriations , Affects Intramural Program

March 11, 1994

NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction

April 28, 2006

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989